Featured Press Releases

HNSA-5487 reduced IgG by over 95% in a first-in-human trial, showing redosing potential

HNSA-5487 reduced IgG by over 95% in a first-in-human trial, showing redosing potential

CollPlant Biotechnologies Announces First Quarter 2025 Financial Results and Issues Corporate Update

CollPlant Biotechnologies Announces First Quarter 2025 Financial Results and Issues Corporate Update

  • 28 May 2025

CollPlant Biotechnologies a regenerative and aesthetics medicine company developing innovative...

Aptar’s Nasal Unidose System will deliver neffy® (epinephrine nasal spray), the first FDA-approved needle-free treatment for Type I allergic reactions, including anaphylaxis

Aptar’s Nasal Unidose System will deliver neffy® (epinephrine nasal spray), the first FDA-approved needle-free treatment for Type I allergic reactions, including anaphylaxis

SciTech Development reveals promising Phase 1A trial results for T-cell non-Hodgkin lymphoma therapy

SciTech Development reveals promising Phase 1A trial results for T-cell non-Hodgkin lymphoma therapy

Emerald Clinical Trials Rebrands from George Clinical

Emerald Clinical Trials Rebrands from George Clinical

Actinium Pharmaceuticals publishes Actimab-A + CLAG-M trial results for relapsed/refractory AML in Leukemia

Actinium Pharmaceuticals publishes Actimab-A + CLAG-M trial results for relapsed/refractory AML in Leukemia

Neurocrine Biosciences Presents New Post-Hoc Data from the KINECT®-HD Study, Demonstrating a Significant Reduction in Disease Burden with INGREZZA® (valbenazine) Capsules for Huntington

Neurocrine Biosciences Presents New Post-Hoc Data from the KINECT®-HD Study, Demonstrating a Significant Reduction in Disease Burden with INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea

  • Neurocrine Biosciences, Inc.
  • 30 Jun 2025
Innovent Announces Approval from China

Innovent Announces Approval from China's NMPA for Mazdutide, the First Dual GCG/GLP-1 Receptor Agonist, for Chronic Weight Management

  • Innovent Biologics
  • 30 Jun 2025
To Redefine Specialty Care, Craft Telemedicine Launches with a Human-Centered Platform

To Redefine Specialty Care, Craft Telemedicine Launches with a Human-Centered Platform

  • Craft Telemedicine
  • 27 Jun 2025
Alafair Biosciences Announces Enrollment of First Patient in Multi-Center Study Testing VersaWrap® Tendon Protector for Achilles Repair

Alafair Biosciences Announces Enrollment of First Patient in Multi-Center Study Testing VersaWrap® Tendon Protector for Achilles Repair

  • Alafair Biosciences, Inc.
  • 25 Jun 2025
With New Offerings Like MIC+B12 Injections, Metformin Combinations, and More, Shed Expands Its Weight Management Support

With New Offerings Like MIC+B12 Injections, Metformin Combinations, and More, Shed Expands Its Weight Management Support

  • Shed
  • 25 Jun 2025
enGene’s Detalimogene Receives RMAT Designation from the FDA, Opening the Path for Expedited Review in High-Risk, Non-Muscle Invasive Bladder Cancer

enGene’s Detalimogene Receives RMAT Designation from the FDA, Opening the Path for Expedited Review in High-Risk, Non-Muscle Invasive Bladder Cancer

  • enGene Holdings Inc.
  • 25 Jun 2025
Webinar: Leverage AI for Operational Excellence and Strategic Cost Management

Most Popular
July   2025
M T W T F S S
  1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30 31      

User Area

Discover

Engage with Us

© 2024 Pharmaceutical Era — A product of HISSM. All Rights Reserved.